{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:39:29Z","timestamp":1790015969045,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a contagious pathogen causing acute respiratory infections (ARIs). Symptoms range from mild upper respiratory tract infections to potentially life\u2010threatening lower respiratory tract disease (LRTD). In adults \u226560\u2009years old, vaccine efficacy of a candidate vaccine for older adults (RSVPreF3 OA) was 71.7% against RSV\u2010ARI and 82.6% against RSV\u2010LRTD (AReSVi\u2010006\/NCT04886596). We present the patient\u2010reported outcomes (PROs) from the same trial at the end of the first RSV season in the northern hemisphere (April 2022).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase 3 trial, adults aged \u226560\u2009years were randomized (1:1) to receive one dose of RSVPreF3 OA vaccine or placebo. PROs were assessed using InFLUenza Patient\u2010Reported Outcome (FLU\u2010PRO), Short Form\u201012 (SF\u201012), and EuroQol\u20105 Dimension (EQ\u20105D) questionnaires. Peak FLU\u2010PRO Chest\/Respiratory scores during the first 7\u2009days from ARI episode onset were compared using a Wilcoxon test. Least squares mean (LSMean) of SF\u201012 physical functioning (PF) and EQ\u20105D health utility scores were estimated using mixed effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the RSVPreF3 OA group (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200912,466), 27 first RSV\u2010ARI episodes were observed versus 95 in the Placebo group (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200912,494). Median peak FLU\u2010PRO Chest\/Respiratory scores were lower in RSVPreF3 OA (1.07) versus Placebo group (1.86);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0258. LSMean group differences for the PF and EQ\u20105D health utility score were 7.00 (95% confidence interval [CI]: \u22129.86, 23.85;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.4125) and 0.0786 (95% CI: \u22120.0340, 0.1913;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.1695).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The RSVPreF3 OA vaccine, in addition to preventing infection, attenuated the severity of RSV\u2010associated symptoms in breakthrough infections, with trends of reduced impact on PF and health utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/irv.13236","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T05:26:15Z","timestamp":1706937975000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus\u2010associated disease in breakthrough infections in adults \u226560\u2009years of age"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-0111","authenticated-orcid":false,"given":"Desmond","family":"Curran","sequence":"first","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Matthews","sequence":"additional","affiliation":[{"name":"Freelance c\/o GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliazar Sabater","family":"Cabrera","sequence":"additional","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Narejos","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"CAP Centelles  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina P\u00e9rez","family":"Breva","sequence":"additional","affiliation":[{"name":"Vaccine Research FISABIO\u2010Public Health  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"R\u00e4met","sequence":"additional","affiliation":[{"name":"Finnish Vaccine Research  Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Helman","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine George Washington University School of Medicine &amp; Health Sciences  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Park","sequence":"additional","affiliation":[{"name":"Korea University Ansan Hospital  Ansan Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino F.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Institute of Laboratory Medicine and Vaccination Centre Klinikum W\u00fcrzburg Mitte  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Maria Galan","family":"Melendez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Fundacion Alcorcon  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Medizentrum Essen Borbeck  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Roy","sequence":"additional","affiliation":[{"name":"Medicor Research  Greater Sudbury Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Stephan","sequence":"additional","affiliation":[{"name":"SGS proDERM  Schenefeld Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Molnar","sequence":"additional","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusine","family":"Kostanyan","sequence":"additional","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John H.","family":"Powers","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine George Washington University School of Medicine &amp; Health Sciences  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Hulstr\u00f8m","sequence":"additional","affiliation":[{"name":"GSK  Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Members of the AReSVi\u2010006 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/20499361221091413"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043951"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102586"},{"key":"e_1_2_10_5_1","unstructured":"Centers for Disease Control and Prevention.Transmission of RSV (respiratory syncytial virus).2022. Accessed February 10 2023.https:\/\/www.cdc.gov\/rsv\/about\/transmission.html"},{"key":"e_1_2_10_6_1","unstructured":"Centers for Disease Control and Prevention.RSV in older adults and adults with chronic medical conditions.2022. Accessed February 10 2023.https:\/\/www.cdc.gov\/rsv\/high-risk\/older-adults.html"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.2747"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12929"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13043"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209604"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010015\u20101330\u20100"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194180"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895\u20104356(98)00109\u20107"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650\u2010199603000\u201000003"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.5.551"},{"key":"e_1_2_10_17_1","unstructured":"Food and Drug Administration.Guidance for industry\u2014patient\u2010reported outcome measures: use in medical product development to support labeling claims.2009. Accessed September 14 2023.https:\/\/www.fda.gov\/media\/77832\/download"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17726018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/03610929808832160"},{"key":"e_1_2_10_20_1","unstructured":"World Health Organization.WHO's work on the UN Decade of Healthy Ageing (2021\u20102030).2023. Accessed February 10 2023.https:\/\/www.who.int\/initiatives\/decade-of-healthy-ageing"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2020.05.018"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20105\u201070"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gly150"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir959"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a118485"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000197565.45345.4e"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2020"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010018\u20100597\u20104"}],"updated-by":[{"DOI":"10.1111\/irv.70088","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000}},{"DOI":"10.1111\/irv.13364","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000}}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.13236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:43:15Z","timestamp":1724805795000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.13236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/irv.13236"],"URL":"https:\/\/doi.org\/10.1111\/irv.13236","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/IRV.13236\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13236\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13236\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13236\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13236\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13236\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13236\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13236"}}